Literature DB >> 21806379

Carbonic anhydrase inhibitors and activators for novel therapeutic applications.

Claudiu T Supuran1.   

Abstract

Carbonic anhydrases (CAs, Enzyme Commission number 4.2.1.1) catalyze a simple but fundamental reaction, CO(2) hydration to yield bicarbonate and protons. CAs belonging to the α-, β-, γ-, δ- and ζ-families are found in many organisms all over the phylogenetic tree and their inhibition/activation have been studied in detail, leading to various therapeutic applications. Inhibition of mammalian α-CAs is exploited by some diuretics, whereas antiglaucoma, anticonvulsant, anti-obesity, altitude sickness and anti-tumor drugs/diagnostic agents target various of the 15 isoforms described so far in these organisms. Activation of some CAs may also have applications in therapy. Bacterial and fungal β-CA inhibitors or nematode α-CA inhibitors have been described that may lead to novel classes of anti-infectives.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21806379     DOI: 10.4155/fmc.11.69

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  35 in total

1.  Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo.

Authors:  Fabrizio Carta; Mayank Aggarwal; Alfonso Maresca; Andrea Scozzafava; Robert McKenna; Emanuela Masini; Claudiu T Supuran
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

2.  Crystal Structure of a Tetrameric Type II β-Carbonic Anhydrase from the Pathogenic Bacterium Burkholderia pseudomallei.

Authors:  Andrea Angeli; Marta Ferraroni; Mariana Pinteala; Stelian S Maier; Bogdan C Simionescu; Fabrizio Carta; Sonia Del Prete; Clemente Capasso; Claudiu T Supuran
Journal:  Molecules       Date:  2020-05-12       Impact factor: 4.411

3.  Utility of thermo-alkali-stable γ-CA from polyextremophilic bacterium Aeribacillus pallidus TSHB1 in biomimetic sequestration of CO2 and as a virtual peroxidase.

Authors:  Himadri Bose; Tulasi Satyanarayana
Journal:  Environ Sci Pollut Res Int       Date:  2017-03-14       Impact factor: 4.223

4.  Glycomimetic Based Approach toward Selective Carbonic Anhydrase Inhibitors.

Authors:  Debora Pratesi; Camilla Matassini; Andrea Goti; Andrea Angeli; Fabrizio Carta; Claudiu T Supuran; Rolando Spanevello; Francesca Cardona
Journal:  ACS Med Chem Lett       Date:  2020-03-11       Impact factor: 4.345

Review 5.  Bioactive heterocycles containing endocyclic N-hydroxy groups.

Authors:  Reshma Rani; Carlotta Granchi
Journal:  Eur J Med Chem       Date:  2014-11-18       Impact factor: 6.514

6.  Continued Structural Exploration of Sulfocoumarin as Selective Inhibitor of Tumor-Associated Human Carbonic Anhydrases IX and XII.

Authors:  Simone Giovannuzzi; Clemente Capasso; Alessio Nocentini; Claudiu T Supuran
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

7.  Carbonic anhydrase inhibitors: design, synthesis, and biological evaluation of novel sulfonyl semicarbazide derivatives.

Authors:  Jayashree Pichake; Prashant S Kharkar; Mariangela Ceruso; Claudiu T Supuran; Mrunmayee P Toraskar
Journal:  ACS Med Chem Lett       Date:  2014-05-16       Impact factor: 4.345

8.  Sulfonamides with Potent Inhibitory Action and Selectivity against the α-Carbonic Anhydrase from Vibrio cholerae.

Authors:  Mariangela Ceruso; Sonia Del Prete; Zeid Alothman; Clemente Capasso; Claudiu T Supuran
Journal:  ACS Med Chem Lett       Date:  2014-05-23       Impact factor: 4.345

9.  Expression of the CHOP-inducible carbonic anhydrase CAVI-b is required for BDNF-mediated protection from hypoxia.

Authors:  Tori A Matthews; Allyssa Abel; Chris Demme; Teresa Sherman; Pei-wen Pan; Marc W Halterman; Seppo Parkkila; Keith Nehrke
Journal:  Brain Res       Date:  2013-11-23       Impact factor: 3.252

10.  Chromene-Containing Aromatic Sulfonamides with Carbonic Anhydrase Inhibitory Properties.

Authors:  Andrea Angeli; Victor Kartsev; Anthi Petrou; Mariana Pinteala; Volodymyr Brovarets; Sergii Slyvchuk; Stepan Pilyo; Athina Geronikaki; Claudiu T Supuran
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.